RecruitingNot ApplicableNCT07093606
Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
Sponsor
Sohag University
Enrollment
100 participants
Start Date
Jul 14, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Exclusion Criteria1
- Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEltrombopag
ITP patients will receive Eltrombopag and evulate occurance of liver disordres .
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07093606
Related Trials
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT071948508 locations
OM336 in Autoimmune Cytopenias
NCT070839603 locations
Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study
NCT071336591 location
RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia
NCT0691934136 locations
Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia
NCT068131571 location